Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.
作者信息
Kornauth Christoph, Herbaux Charles, Boidol Bernd, Guillemette Chantal, Caron Patrick, Mayerhöfer Marius E, Poulain Stéphanie, Tournilhac Olivier, Pemovska Tea, Chong Stephen J F, Van der Kouwe Emiel, Kazianka Lukas, Hopfinger Georg, Heintel Daniel, Jäger Roland, Raderer Markus, Jäger Ulrich, Simonitsch-Klupp Ingrid, Sperr Wolfgang R, Kubicek Stefan, Davids Matthew S, Staber Philipp B
机构信息
Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna.
Department of Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston.
出版信息
Haematologica. 2021 Aug 1;106(8):2251-2256. doi: 10.3324/haematol.2020.271304.
Abstract
摘要
Zotero 插件